InterCure Ltd.
NASDAQ:INCR · NASDAQ Global Market
+$0.08 today
Vol 0.02M · Avg 0.04M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:INCR · Revenue to Net Income
Key Ratios
Analysis
$243.1M of revenue converted into -$70.9M of net income for the selected period. Gross margin is 15.6% and net margin is -16.0%, showing how much revenue survives after costs and taxes. EPS is $-1.61, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $270.2M +13.1% | $238.8M -32.8% | $355.6M -8.5% | $388.7M +76.9% | $219.7M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $237.0M +13.6% | $208.6M -16.7% | $250.5M +7.2% | $233.6M +81.7% | $128.5M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $33.2M +9.8% | $30.2M -71.2% | $105.1M -32.2% | $155.1M +70.2% | $91.1M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 12.3% -0.4pp | 12.7% -16.9pp | 29.6% -10.3pp | 39.9% -1.6pp | 41.5% | 9.8% | 28.9% | 38.3% |
| Research & Development | $390.0K -5.8% | $414.0K +6.7% | $388.0K -38.6% | $632.0K -48.8% | $1.2M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $80.4M -5.0% | $84.6M -1.9% | $86.2M -11.4% | $97.3M +82.0% | $53.5M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $26.4M -72.9% | $97.4M -33.6% | $146.7M +40.4% | $104.5M +65.9% | $62.9M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $17.1M +11.6% | $15.4M +16.7% | $13.2M +12.5% | $11.7M +58.2% | $7.4M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$7.3M +85.8% | -$51.3M -114.7% | -$23.9M -134.0% | $70.2M +125.3% | $31.2M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -2.7% +18.8pp | -21.5% -14.8pp | -6.7% -24.8pp | 18.1% +3.9pp | 14.2% | 5.6% | 46.3% | 42.0% |
| Operating Income | $6.7M +110.0% | -$67.2M -61.7% | -$41.6M -182.1% | $50.6M +79.6% | $28.2M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 2.5% +30.6pp | -28.1% -16.4pp | -11.7% -24.7pp | 13.0% +0.2pp | 12.8% | 16.6% | 24.1% | 22.0% |
| Interest Income | $1.6M -42.4% | $2.7M -40.6% | $4.5M +438.7% | $844.0K +549.2% | $130.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $19.7M -4.8% | $20.6M -14.8% | $24.2M +64.9% | $14.7M +191.2% | $5.0M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$50.8M -152.7% | -$20.1M -2.0% | -$19.7M -190.6% | -$6.8M +28.2% | -$9.5M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$44.1M +49.5% | -$87.3M -42.5% | -$61.3M -239.8% | $43.8M +134.0% | $18.7M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -16.3% +20.2pp | -36.6% -19.3pp | -17.2% -28.5pp | 11.3% +2.8pp | 8.5% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | -$7.3M +49.6% | -$14.5M -746.4% | $2.2M +2317.2% | $93.0K -99.2% | $11.4M | $1.3B | -$1.6B | $745.2M |
| Net Income | -$35.7M +47.3% | -$67.8M -9.4% | -$62.0M -238.2% | $44.8M +855.6% | $4.7M | $4.9B | $4.8B | $4.7B |
| Net Margin | -13.2% +15.2pp | -28.4% -11.0pp | -17.4% -29.0pp | 11.5% +9.4pp | 2.1% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$1 +55.6% | -$1 -4.4% | -$1 -237.4% | $1 +725.0% | $0 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$1 +55.6% | -$1 -4.4% | -$1 -237.4% | $1 +800.0% | $0 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $56.8M +18.9% | $47.8M +4.8% | $45.6M +0.5% | $45.4M +17.8% | $38.5M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $56.8M +18.9% | $47.8M +4.8% | $45.6M +0.5% | $45.4M +11.1% | $40.8M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Edap Tms S.a.
EDAP
$178.23M
Unicycive Therapeutics, Inc.
NASDAQ:UNCY
$153.02M
Assertio Holdings, Inc.
NASDAQ:ASRT
$151.86M
American Well Corporation
NYSE:AMWL
$145.20M
Cardiol Therapeutics Inc.
NASDAQ:CRDL
$121.04M
Repare Therapeutics Inc.
RPTX
$114.24M
Fortress Biotech, Inc.
NASDAQ:FBIO
$95.01M
CAMP4 Therapeutics Corporation
NASDAQ:CAMP
$84.11M
MindWalk Holdings Corp.
NASDAQ:HYFT
$72.87M
Biomea Fusion, Inc.
NASDAQ:BMEA
$71.40M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does INCR generate?
InterCure Ltd. (INCR) reported $270.20M of revenue in fiscal 2025.
Is INCR profitable?
InterCure Ltd. (INCR) reported -$35,710,000.00 of net income, with a net margin of -13.2%.
Explore More
Continue the stock analysis
Jump to another research area for this company.